SCHEMBL14720719

SCHEMBL14720719

CCOC(=O)CN(Cc1cc(I)cc(CN(CC(=O)OCC)Cc2cc(Br)cc(C(=O)OCC)n2)n1)Cc1cc(Br)cc(C(=O)OCC)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GABRA2 P47869 4/20 0.35
GABRB2 P47870 3/20 0.35
CYP1A2 P05177 1/20 0.35
MEP1B Q16820 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA4 P48169 1/20 0.33
GABRA6 Q16445 1/20 0.33
GSK3B P49841 1/20 0.32
POLB P06746 3/20 0.32
MAPT P10636 3/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
PKM P14618 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14721258 0.81 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2GABRA2GABRB2CYP1A2
SCHEMBL14720912 0.81 KMT2A (0.44) ALDH1A1SMN1; SMN2MEP1BPOLBMAPT
SCHEMBL15104854 0.81 CA12 (0.41) ALDH1A1SMN1; SMN2CYP1A2MAPTNPSR1
SCHEMBL14720808 0.79 L3MBTL1 (0.41) ALDH1A1SMN1; SMN2POLBMAPTPKM
SCHEMBL27803494 0.78 CA12 (0.37) ALDH1A1SMN1; SMN2CYP1A2MAPTNPSR1
SCHEMBL6027858 0.78 NR1D1 (0.34) ALDH1A1SMN1; SMN2CYP1A2MEP1BMEN1
SCHEMBL22854579 0.76 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2GABRA2GABRB2CYP1A2
SCHEMBL14720800 0.76 MEN1 (0.35) ALDH1A1SMN1; SMN2GABRA2GABRB2CYP1A2
SCHEMBL3094672 0.75 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2GABRA2GABRB2CYP1A2
SCHEMBL3008182 0.74 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2GABRA2GABRB2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2753674-B1 LUMINESCENT LANTHANIDE CHELATES HAVING THREE CHROMOPHORES AND THEIR USE DHR FINLAND OY (FI) 2016-02-10 EP disclosed
US-20130210165-A1 Luminescent Lanthanide Chelates Having Three Chromophores and Their Use DHR FINLAND OY (FI) 2013-08-15 US disclosed
WO-2013026790-A9 LUMINESCENT LANTHANIDE CHELATES HAVING THREE CHROMOPHORES AND THEIR USE DHR FINLAND OY (FI) 2013-05-23 WO disclosed
WO-2013026790-A1 LUMINESCENT LANTHANIDE CHELATES HAVING THREE CHROMOPHORES AND THEIR USE DHR FINLAND OY (FI) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210165-A1 Luminescent Lanthanide Chelates Having Three Chromophores and Their Use GLB1, SSB, LGALS3BP ALDH1A1 3095/4885SMN1; SMN2 4521/4885GABRA2 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.